1999
Narrowband (311-nm) UV-B Therapy for Small Plaque Parapsoriasis and Early-Stage Mycosis Fungoides
Search citation statements
Paper Sections
Select...
131
19
4
1
Citation Types
2
94
4
4
Year Published
2000
2026
Publication Types
Select...
127
10
9
Relationship
0
146
Authors
Journals
Cited by 146 publications
(104 citation statements)
References 13 publications
2
94
4
4
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…In IA patients CR was achieved in 84 and 89% and with IB patients in 78 and 44% in NB and BB groups, respectively, after a median of 10 weeks, comparable to all previously reported results with skin‐targeted treatments. Overall, total doses of NB UVB needed to achieve CR (19 J/cm 2 ) were comparable to previously reported (16.3–96.7 J/cm 2 ) 15,23,25 …”
Section: Discussion
supporting
confidence: 88%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…In IA patients CR was achieved in 84 and 89% and with IB patients in 78 and 44% in NB and BB groups, respectively, after a median of 10 weeks, comparable to all previously reported results with skin‐targeted treatments. Overall, total doses of NB UVB needed to achieve CR (19 J/cm 2 ) were comparable to previously reported (16.3–96.7 J/cm 2 ) 15,23,25 …”
Section: Discussion
supporting
confidence: 88%
“…PUVA has been reported to be more effective than BB UVB for stage I MF patients in only one Italian retrospective study 34 . Such a conclusion could not be drawn from our and previous UVB studies 15,20–25 in comparison to PUVA historical data 9–17 . Deeper penetration of UVA into the skin is considered to be one of the advantages of the PUVA treatment responsible for ‘more complete’ histological improvement.…”
Section: Discussion
contrasting
confidence: 58%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…While we used a fixed starting dose of 0.2 J ⁄ cm 2 and fixed increments of 0.1 J ⁄ cm 2 per day, Hofer et al started with 70% of the minimal erythema dose and increased the dose by 20% every week. 15 The mean time until relapse of the disease was similar in both studies, 7 months (range 7-118 weeks) in our study and 6 months (range 2-15 months) in the study by Hofer et al This suggests that early relapses of the disease are the most troublesome shortcoming of NB-UVB therapy for SPP.…”
Section: Report
supporting
confidence: 82%
“…A previous study reported that NB-UVB therapy achieved CR in all patients with SPP (n ¼ 14) and five of six patients with early stage MF. 15 The total dose of NB-UVB required to achieve CR was lower in that study (16.3 J ⁄ cm 2 , range 7.4-36.4 J ⁄ cm 2 ) than in ours. Similarly, fewer treatments were needed (mean 20, range [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29].…”
Section: Report
contrasting
confidence: 60%
